Navigation Links
MEDRAD® Announces New Head of Interventional Business
Date:3/29/2011

WARRENDALE, Pa., March 29, 2011 /PRNewswire/ -- Today MEDRAD, INC. announced that Jack Darby has joined the company as vice president of MEDRAD Interventional. In his new role, Darby will act as general manager of both the diagnostic and therapeutic lines of the business on a global scale, and will also join MEDRAD's executive leadership team.  

(Photo:  http://photos.prnewswire.com/prnh/20110329/NE73380 )

(Logo: http://photos.prnewswire.com/prnh/20040309/MEDRADLOGO)

Darby brings almost 20 years of experience in the medical device industry to the role, with most of those years in the interventional cardiology space. He comes to MEDRAD from AGA Medical Corporation, where he most recently served as senior vice president of Global Marketing and Distributor Sales, gaining deep experience in the field of the structural heart. Prior to AGA, Darby spent over 15 years at Cordis, a Johnson & Johnson company, starting as an angiographic sales representative. His leadership ability, sales/marketing acumen and international experience ultimately resulted in his role as vice president of commercial operations and global stent marketing.

"Jack's broad base of experience in the interventional space and combination drug-device products will greatly complement our patient-focused goals for the interventional business," says MEDRAD President and CEO Sam Liang. "With the support of his leadership, we plan to extend our product innovation and customer satisfaction footprint within this growing, global market."

With manufacturing facilities in both Minneapolis, MN and Pittsburgh, PA, MEDRAD Interventional manufactures and markets segment-leading medical devices such as AngioJet® Thrombectomy Systems, MEDRAD Avanta® Fluid Management Injector Systems and catheters, Mark V ProVis® Angiographic Contrast Injectors, FETCH® Aspiration Catheters and the GuardDOG® Occlusion System.

About MEDRAD, INC.

MEDRAD, INC. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Forward-looking statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
2. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
3. Boston Scientific Announces Its ACC 2011 Schedule
4. Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements
5. Dendreon Announces Webcast Presentations at Upcoming Conferences
6. Diversified Medical Equipment & Supplies Corporation Announces New Home Care Medical Supply Division
7. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
8. JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
9. Ascension Orthopedics Announces Market Release of TITAN™ Modular Shoulder Fracture Prosthesis
10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
11. Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... poor, the new feel good program from Leany Greeny delivers positive results in ... can rejuvenate overall health and kickstart the metabolism. Fitting seamlessly into hectic work ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published author, ... field of addiction and homeless services, including more than a decade of addiction ...
Breaking Medicine News(10 mins):